{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:19:33Z","timestamp":1768562373994,"version":"3.49.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":450,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"MSK","award":["P50 CA192937-01A1"],"award-info":[{"award-number":["P50 CA192937-01A1"]}]},{"name":"Memorial Sloan Kettering Cancer Center Core","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1093\/annonc\/mdy219","type":"journal-article","created":{"date-parts":[[2018,6,12]],"date-time":"2018-06-12T19:09:48Z","timestamp":1528830588000},"page":"1622-1623","source":"Crossref","is-referenced-by-count":6,"title":["Surrogate end points in lymphoma"],"prefix":"10.1016","volume":"29","author":[{"given":"C.L.","family":"Batlevi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1093\/annonc\/mdy219_bb0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-Year Experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdy219_bb0015","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdy219_bb0020","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy219_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1093\/annonc\/mdy219_bb0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy219_bb0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419341353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/8\/1622\/25505000\/mdy219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T21:48:36Z","timestamp":1631828916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419341353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S0923753419341353"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy219","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}